Hologic, Inc. $HOLX Shares Sold by Trillium Asset Management LLC

Trillium Asset Management LLC trimmed its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 23.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,654 shares of the medical equipment provider’s stock after selling 2,289 shares during the period. Trillium Asset Management LLC’s holdings in Hologic were worth $499,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of HOLX. Chung Wu Investment Group LLC purchased a new stake in shares of Hologic in the second quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd increased its position in shares of Hologic by 193.6% in the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 273 shares in the last quarter. Zions Bancorporation National Association UT purchased a new stake in shares of Hologic in the first quarter valued at approximately $34,000. Cromwell Holdings LLC increased its position in shares of Hologic by 307.0% in the second quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock valued at $38,000 after buying an additional 436 shares in the last quarter. Finally, Allworth Financial LP increased its position in shares of Hologic by 46.0% in the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock valued at $40,000 after buying an additional 216 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on HOLX shares. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $60.00 to $80.00 in a research report on Wednesday, July 9th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $78.00 price objective on shares of Hologic in a research report on Wednesday, October 22nd. UBS Group boosted their price objective on Hologic from $65.00 to $70.00 and gave the company a “neutral” rating in a research report on Thursday, July 31st. Weiss Ratings restated a “hold (c)” rating on shares of Hologic in a research report on Friday, October 31st. Finally, Morgan Stanley lifted their price target on Hologic from $65.00 to $69.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and thirteen have given a Hold rating to the stock. Based on data from MarketBeat, Hologic currently has a consensus rating of “Hold” and a consensus price target of $79.23.

Hologic Stock Performance

Shares of NASDAQ:HOLX opened at $74.23 on Thursday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The business’s 50 day moving average price is $68.70 and its 200-day moving average price is $64.93. The firm has a market capitalization of $16.51 billion, a PE ratio of 30.80, a P/E/G ratio of 2.54 and a beta of 0.65. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $81.13.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.03. The firm had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.03 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The business’s revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the company posted $1.01 earnings per share. As a group, equities research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Hologic news, Director Christiana Stamoulis sold 7,402 shares of the business’s stock in a transaction on Monday, October 20th. The stock was sold at an average price of $73.07, for a total transaction of $540,864.14. Following the transaction, the director owned 47,336 shares of the company’s stock, valued at approximately $3,458,841.52. The trade was a 13.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Stephen P. Macmillan sold 138,358 shares of the business’s stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the transaction, the chief executive officer directly owned 1,234,624 shares in the company, valued at $82,682,769.28. This trade represents a 10.08% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 1.88% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.